Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of Talampanel in Glioblastoma Multiforme

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries Identifier:
First received: December 19, 2005
Last updated: April 20, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2011
  Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 16, 2011